OCS vs. LRMR, ANL, TRDA, TVTX, LXRX, SLRN, ATXS, VERV, CRBP, and KALV
Should you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Larimar Therapeutics (LRMR), Adlai Nortye (ANL), Entrada Therapeutics (TRDA), Travere Therapeutics (TVTX), Lexicon Pharmaceuticals (LXRX), Acelyrin (SLRN), Astria Therapeutics (ATXS), Verve Therapeutics (VERV), Corbus Pharmaceuticals (CRBP), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical preparations" industry.
Oculis (NASDAQ:OCS) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk, institutional ownership and community ranking.
Oculis has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.
22.3% of Oculis shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 4.3% of Larimar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Larimar Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -6,712.02%. Larimar Therapeutics' return on equity of -35.69% beat Oculis' return on equity.
Larimar Therapeutics received 10 more outperform votes than Oculis when rated by MarketBeat users. However, 85.71% of users gave Oculis an outperform vote while only 60.87% of users gave Larimar Therapeutics an outperform vote.
Oculis presently has a consensus price target of $30.17, indicating a potential upside of 151.91%. Larimar Therapeutics has a consensus price target of $20.00, indicating a potential upside of 171.00%. Given Larimar Therapeutics' higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Oculis.
Larimar Therapeutics has lower revenue, but higher earnings than Oculis. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.
In the previous week, Oculis had 8 more articles in the media than Larimar Therapeutics. MarketBeat recorded 16 mentions for Oculis and 8 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.84 beat Oculis' score of 0.24 indicating that Larimar Therapeutics is being referred to more favorably in the news media.
Summary
Larimar Therapeutics beats Oculis on 11 of the 16 factors compared between the two stocks.
Get Oculis News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
